Navigation Links
Actavis Full Year 2012 Net Revenue Increases 29% to $5.91 Billion
Date:2/19/2013

ion agreement. 

The reconciliation table is based in part on management's estimate of non-GAAP net income for the year ending December 31, 2013.  Actavis expects certain known GAAP charges for 2013, as presented in the schedule above.  Other GAAP charges that may be excluded from non-GAAP net income are possible, but their amounts are dependent on numerous factors that we currently cannot ascertain with sufficient certainty or are presently unknown.  These GAAP charges are dependent upon future events and valuations that have not yet been performed.

The following table presents a reconciliation of forecasted net income for the twelve months ending December 31, 2013 to adjusted EBITDA:Table 7Actavis, Inc.Reconciliation Table - Forecasted Adjusted EBITDA(Unaudited; in millions)Forecast for Twelve Months
Ending December 31, 2013LowHighGAAP net income

$
440$
490Plus:Interest expense

215215Interest income

(1)(1)Provision for income taxes

185200Depreciation (includes accelerated depreciation)

195195Amortization

625630EBITDA

1,6591,729Adjusted for:Global supply chain initiative

66Acquisition and licensing charges

150150Non-cash impairment charges Non-recurring (gains) losses Share-based compensation

5555Adjusted EBITDA

$
,870$
,940The reconciliation table is based in part on management's estimate of adjusted EBITDA for the year ending December 31, 2013.  Actavis expects certain known GAAP charges for 2013, as presented in the schedule above.  Other GAAP charges that may be excluded from estimated EBITDA are possible, but their amounts are dependent on numerous factors that we currently cannot ascertain with sufficient certainty or are presently unknown.  These GAAP charges are dependent upon future events and valuations that have not yet been performed.

(Logo:

SOURCE Actavis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Watson to Acquire Actavis Group for EUR4.25 Billion
2. Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended-Release Tablets)
3. Actavis Launches Generic Equivalent of Adalat® CC 90mg (Nifedipine Extended-Release Tablets, USP)
4. Watson and Actavis Receive FTC Second Request
5. Watson Announces New Name -- Actavis -- for Global Operations
6. Watson Pharmaceuticals, Inc. is Now Actavis, Inc.
7. Actavis, Inc. to Host Fourth Quarter 2012 Earnings Conference Call and Webcast
8. Actavis, Inc. to Present at the RBC Capital Markets Healthcare Conference
9. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
10. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
11. Aethlon Medical Note: Fiscal Year Revenue Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... , July 1, 2015 Qiming Venture ... to Managing Partner effective immediately. William ... has lead and participated in many Qiming healthcare deals, ... in the Chinese market. Qiming, s success in healthcare ... he has distinguished himself with his outstanding advocacy and ...
(Date:7/1/2015)... 1, 2015 ExeGi Pharma, a company focused ... announced today that it has been granted a product ... Products Directorate (NNHPD) to sell Visbiome™ in ... by Professor Claudio De Simone , MD, PhD ... Professor De Simone recently signed an exclusive agreement with ...
(Date:7/1/2015)... -- According to a new market research ... (Calcium Phosphate, Lipofection, Dendrimers), Physical (Electroporation, Nucleofection), Viral), by ... to 2020", published by MarketsandMarkets, the Transfection Reagents and ... by 2020 with a CAGR of 7.2% from 2014 ... ables and 33 F igures ...
Breaking Medicine Technology:Qiming Announces the Promotion of William Hu to Managing Partner 2ExeGi Pharma Secures Canadian Approval For Well Studied Probiotic 2ExeGi Pharma Secures Canadian Approval For Well Studied Probiotic 3Transfection Reagents and Equipment Market Worth $957.9 Million by 2020 2Transfection Reagents and Equipment Market Worth $957.9 Million by 2020 3Transfection Reagents and Equipment Market Worth $957.9 Million by 2020 4
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... As if ... symptom found in a significant number of women: leg pain. Northeast Houston Vein Center ... Leg pain, a symptom of venous reflux disease, is underdiagnosed and often overlooked. Many ...
(Date:7/1/2015)... ... ... Trevor L. Williams, DMD holds a Bachelor of Science degree in Biomedical Sciences ... in Microbiology. He graduated from the University of Florida College of Dentistry in 2015 ... and the Academy of General Dentistry. Dr. Williams was born in Tampa and is ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... ... solution provider of IBM software products, announced today that it has received trademark ... the integration, display and detailed analysis of data from multiple sources providing an ...
(Date:7/1/2015)... Raleigh, NC (PRWEB) , ... July 01, 2015 ... ... Britain’s 2013 mesothelioma compensation law has just published a top ten list they ... on the report. Click here to read it now. , ...
(Date:7/1/2015)... , ... July 01, 2015 , ... Author Francesca Camp wasn’t always a ... her lap, so too did her support of the practice; a terrible car accident years ... her new book, “Do I Need It ? (And What if I Do?): Answers ...
Breaking Medicine News(10 mins):Health News:Northeast Houston Vein Center Offers Tips for Women with Leg Pain 2Health News:Northeast Houston Vein Center Offers Tips for Women with Leg Pain 3Health News:Trevor L. Williams, D.M.D. Joins Enlow & Vance Dental Partners in Tampa, Florida 2Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 2Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 3Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 4Health News:New Report Identifies Top 10 Mesothelioma Research Priorities, According to Surviving Mesothelioma 2Health News:Francesca Camp’s New Book Unmasks Plastic Surgery Advice 2
... sector providers of social care services face a host ... commitment to expanding personal budgets* in social care. The ... expand personal budgets are outlined in ,The impact of ... This new booklet highlights the views of leading ...
... April 1 Anesiva, Inc. (Nasdaq: ANSV ... today announced that its consolidated financial statements for the ... Company,s annual report on Form 10-K filed with the ... a going concern qualification from its independent registered public ...
... notion that antiretrovirals can be postponed till later in ... HIV treatment before the patient,s immune system is too ... finds. , The finding may help settle a debate ... therapy can be deferred until later in the infection ...
... de C.V. (BMV: LAB) ("Genomma Lab" or "the Company") ... Medicinas y Medicamentos Nacionales,S.A.P.I., de C.V., a Mexican company. ... Genomma Lab will sell new product lines,within the categories ... others. , Genomma Lab will ...
... Inc. (NYSE Alternext: ... treatment of wounds using Altrazeal(TM) Transforming Powder Dressing, and data ... at the annual APWCA National Clinical Conference in Philadelphia, April ... presentations and with posters on display during the meeting.Renaat Van ...
... LOCAL HEALTHCARE EXECUTIVE SPEAKS IN DALLAS ON THE PATIENT ... environment in which a patient heals is critical to ... Future must change to meet that need, said ... healthcare conference in Dallas last week.Rumore addressed the national ...
Cached Medicine News:Health News:Third sector gears up to meet 2Health News:Third sector gears up to meet 3Health News:Anesiva Announces Going Concern Opinion and Nasdaq Notice 2Health News:Anesiva Announces Going Concern Opinion and Nasdaq Notice 3Health News:Starting HIV Therapy Earlier Saves Lives 2Health News:Starting HIV Therapy Earlier Saves Lives 3Health News:Genomma Lab Acquires the Mexican Company Medicinas y Medicamentos Nacionales 2Health News:Altrazeal(TM) Clinical Evidence to be Presented at The American Professional Wound Care Association (APWCA) National Clinical Conference 2009 2Health News:Altrazeal(TM) Clinical Evidence to be Presented at The American Professional Wound Care Association (APWCA) National Clinical Conference 2009 3Health News:'Patient Room of the Future' Speeds Healing 2
Our soft guedel airway is clear and has a color coded bite block. Airway has a smooth finish and is Latex Free. Recommended for single use. Non-Sterile....
Rsch color coded Guedel airways offer our best value on oropharyngeal airways. They uniquely combine color coding for size and flexible material without a premium price. Color coded airways are latex...
New - Color Coded Berman Airways. A simple idea makes size identification easier for you., ,Premium upgrade without a premium price. Color Coded Berman airways are latex-free., ,Plastic. Single use...
Plastic. Economical. Single use. Non-Sterile....
Medicine Products: